KR20210139274A - 유기산혈증을 치료하는 방법 - Google Patents

유기산혈증을 치료하는 방법 Download PDF

Info

Publication number
KR20210139274A
KR20210139274A KR1020217029827A KR20217029827A KR20210139274A KR 20210139274 A KR20210139274 A KR 20210139274A KR 1020217029827 A KR1020217029827 A KR 1020217029827A KR 20217029827 A KR20217029827 A KR 20217029827A KR 20210139274 A KR20210139274 A KR 20210139274A
Authority
KR
South Korea
Prior art keywords
coa
alkyl
compound
pharmaceutically acceptable
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217029827A
Other languages
English (en)
Korean (ko)
Inventor
브라이언 왐호프
존 리어돈
로버트 피글러
Original Assignee
헤모시어 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 헤모시어 테라퓨틱스, 인크. filed Critical 헤모시어 테라퓨틱스, 인크.
Publication of KR20210139274A publication Critical patent/KR20210139274A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020217029827A 2019-03-14 2020-03-13 유기산혈증을 치료하는 방법 Ceased KR20210139274A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962818372P 2019-03-14 2019-03-14
US62/818,372 2019-03-14
PCT/US2020/022760 WO2020186216A1 (en) 2019-03-14 2020-03-13 Methods of treating organic acidemias

Publications (1)

Publication Number Publication Date
KR20210139274A true KR20210139274A (ko) 2021-11-22

Family

ID=72426817

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217029827A Ceased KR20210139274A (ko) 2019-03-14 2020-03-13 유기산혈증을 치료하는 방법

Country Status (11)

Country Link
US (1) US20220142955A1 (https=)
EP (1) EP3937922A4 (https=)
JP (1) JP2022525339A (https=)
KR (1) KR20210139274A (https=)
CN (1) CN113557014A (https=)
AU (1) AU2020236023A1 (https=)
BR (1) BR112021018036A2 (https=)
CA (1) CA3133260A1 (https=)
EA (1) EA202192497A1 (https=)
IL (1) IL285822A (https=)
WO (1) WO2020186216A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022216848A1 (en) * 2021-04-06 2022-10-13 Hemoshear Therapeutics, Inc. Methods of treating methylmalonic acidemia and propionic acidemia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1249706B (it) * 1991-09-18 1995-03-09 Sigma Tau Ind Farmaceuti Uso di l-carnitina nella gravidanza a rischio.
AU3889197A (en) * 1996-07-26 1998-02-20 Douglas V Faller Compositions comprising an inducing agent and an anti-viral agent for the treat ment of blood, viral and cellular disorders
US20050027006A1 (en) * 2003-07-28 2005-02-03 Reuben Matalon Methods and materials for treating conditions associated with metabolic disorders
WO2011072086A1 (en) * 2009-12-08 2011-06-16 Hemaquest Pharmaceuticals, Inc. Methods and low dose regimens for treating red blood cell disorders
US20120289476A1 (en) * 2009-12-11 2012-11-15 Jay Allan Barth Methods for treating methylmalonic acidemia
US9018176B2 (en) * 2010-12-02 2015-04-28 Susan Perrine Inducers of hematopoiesis and fetal globin production for treatment of cytopenias and hemoglobin disorders
ES2795798T3 (es) * 2011-07-06 2020-11-24 Ptc Therapeutics Inc Tratamiento de aciduria metilmalónica, aciduria isovalérica, y otras acidurias orgánicas con tocotrienol quinonas
EP2877444B1 (en) * 2012-07-27 2020-09-02 The Broad Institute, Inc. Inhibitors of histone deacetylase
US20180064154A9 (en) * 2015-09-01 2018-03-08 D. Holmes Morton Management of propionate metabolism disorders
JO3543B1 (ar) * 2015-09-28 2020-07-05 Applied Pharma Res تراكيب حمض أميني إصدار معدل تعطى عن طريق الفم
WO2017139697A1 (en) * 2016-02-10 2017-08-17 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
WO2017184583A1 (en) * 2016-04-19 2017-10-26 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anaplerotic agents for treatment of disorders of propionate and long chain fat metabolism

Also Published As

Publication number Publication date
IL285822A (en) 2021-10-31
EP3937922A4 (en) 2022-11-30
CA3133260A1 (en) 2020-09-17
EP3937922A1 (en) 2022-01-19
JP2022525339A (ja) 2022-05-12
US20220142955A1 (en) 2022-05-12
WO2020186216A1 (en) 2020-09-17
CN113557014A (zh) 2021-10-26
BR112021018036A2 (pt) 2021-11-23
EA202192497A1 (ru) 2021-11-18
AU2020236023A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
US20220267780A1 (en) Conjugates of bile acids and their derivatives for active molecules delivery
US20250228816A1 (en) Enhancing autophagy or increasing longevity by administration of urolithins
DK2252283T3 (en) SYNTHETIC TRITERPENOIDS AND METHODS FOR USE IN DISEASE TREATMENT
US11578032B2 (en) Derivatives of sobetirome
CN112870187A (zh) 贝壳杉烷类化合物在制备人体组织中磷酸二酯酶活性的调节剂的药物应用
ES2655455T3 (es) Composiciones para el tratamiento de hipertensión y/o fibrosis
WO2015176539A1 (zh) 异喹啉生物碱衍生物用于制备促进ampk活性的药物的用途
US9260391B2 (en) Hypoglycemic dihydropyridones
KR20210139274A (ko) 유기산혈증을 치료하는 방법
CN105188688A (zh) 用于在非造血性细胞中诱导促红细胞生成素(epo)介导的产生血红蛋白表达和线粒体生物合成的组合物和方法
AU2021361997A9 (en) Metalloenzyme inhibitors for treating cancers, alzheimer's disease, hemochromatosis, and other disorders
TW201400447A (zh) ３－（１５－羥基十五烷基）－２，４，４－三甲基－２－環己烯－１－酮之共結晶
JP5019396B2 (ja) 糖代謝改善剤
JP7224303B2 (ja) 薬剤、組成物、及びそれに関連する方法
JPWO2011058943A1 (ja) Ｍｃｈｒ１アンタゴニスト活性を有する化合物とｎｐｙｙ５受容体アンタゴニスト活性を有する化合物を組み合わせてなる医薬組成物
WO2010098298A1 (ja) 栄養素の消化吸収抑制作用を有する化合物とシクロヘキサンカルボキサミド誘導体を組み合わせてなる医薬組成物
KR20130036493A (ko) 신규한 케르세틴 유도체, 3',4'-디플루오로케르세틴, 그 제조방법 및 그 용도
WO2023154412A1 (en) Anti-inflammatory compounds, pharmaceutical compositions, and treatment methods
WO2024150029A1 (en) Compounds derived from dihydropiridines, pharmaceutical compositions comprising said compounds and method of treatment of muscle disorders comprising administration of said compositions
CN118530166A (zh) 氮杂二苯乙烯类化合物及在代谢综合征防治中的应用
EP2329824A1 (en) Novel pharmaceutical composition for treatment of nociceptive pain
KR20220093208A (ko) 프로스타글란딘 아날로그 및 이들의 용도
JP2019119709A (ja) インスリン分泌促進剤及びインスリン分泌促進方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601